Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
Subscribe To Our Newsletter & Stay Updated
